NCT03825718

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Study Summary

The study is an early, open, single-centered trial.

Want to learn more about this trial?

Request More Info

Interventions

GC007FBIOLOGICAL
GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

Study Locations

FacilityCityStateCountry
Hebei Yanda Ludaopei HospitalSanheHebeiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026